Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

NCT02222428 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: BI 1744 CL/BI 54903 XX FDC
DRUG: BI 54903 XX
DRUG: BI 1744 CL

Sponsor

Boehringer Ingelheim